Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.40 |
| ▸ | CA2 | P00918 | 2/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | APOB | P04114 | 6/20 | 0.34 |
| ▸ | MTTP | P55157 | 6/20 | 0.34 |
| ▸ | SMO | Q99835 | 3/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA7 | P43166 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.34 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.34 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6198196 | 0.79 | CA1 (0.47) | CA1CA2MEN1KMT2AAPOB | |
| SCHEMBL6199831 | 0.79 | CA1 (0.47) | CA1CA2MEN1KMT2AAPOB | |
| SCHEMBL4231484 | 0.79 | CA1 (0.47) | CA1CA2MEN1KMT2AAPOB | |
| Hydrochloric Acid SCHEMBL6203128 | 0.78 | CA1 (0.46) | CA1CA2MEN1KMT2AAPOB | |
| Hydrochloric Acid SCHEMBL6203124 | 0.78 | CA1 (0.46) | CA1CA2MEN1KMT2AAPOB | |
| SCHEMBL6502466 | 0.71 | MEN1 (0.55) | MEN1KMT2AAPOBMTTPMTNR1A | |
| SCHEMBL7906062 | 0.68 | APOB (0.48) | CA1CA2ACHEAPOBMTTP | |
| SCHEMBL7957926 | 0.68 | CA1 (0.45) | CA1CA2MEN1KMT2AAPOB | |
| SCHEMBL6196616 | 0.67 | APOB (0.45) | CA1CA2MEN1KMT2AAPOB | |
| SCHEMBL8765995 | 0.67 | MTNR1A (0.62) | CA1CA2ACHEMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050038035-A1 | Heterocyclic amide compounds as apolipoprotein b inhibitors | DAISO CO., LTD. (JP) | 2005-02-17 | — | — | US | disclosed |
| EP-1472226-A1 | HETEROCYCLIC AMIDE COMPOUNDS AS APOLIPOPROTEIN B INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-11-03 | — | — | EP | disclosed |
| WO-2003045921-A1 | HETEROCYCLIC AMIDE COMPOUNDS AS APOLIPOPROTEIN B INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038035-A1 | Heterocyclic amide compounds as apolipoprotein b inhibitors | APOB, APOL1, CTRB2 | CA1 2761/4885CA2 1990/4885ACHE 1056/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.